Philip Morris International Announces Latest Research Findings on IQOS
With the rapid development of the e-cigarette market, multinational tobacco companies generally regard the development of new tobacco products as a major strategic opportunity for future growth and are making focused, determined investments. Tobacco giant
With the rapid development of the e-cigarette market, multinational tobacco companies generally view the development of new tobacco products as a major strategic opportunity for their future growth and are making significant investments in this area. Tobacco giants in various countries are not satisfied with their current market achievements and continue to push for the expansion of new tobacco product production capacity. Philip Morris International is a prime example.
According to information released today by Philip Morris International, the clinical trial of its most advanced smoke-free tobacco product, IQOS, has concluded with positive results.
IQOS
The research report on IQOS published on the company's official website shows that the company studied the exposure response to the smoke of its smoke-free tobacco products. The study continuously tracked and measured the biological responses of consumers who switched to and used IQOS devices over a period of six months, comparing the final results with those of a group of continuous smokers. The results indicated that after six months, the group that switched to IQOS products showed improvements in eight biological response indicators (mainly clinical risk indicators). This is the latest research finding regarding the company's new product.
Frederic, the president of Philip Morris International's EU region
Earlier, Philip Morris International attempted to enter the U.S. market with IQOS but was rejected by the U.S. Food and Drug Administration (FDA), which claimed that the product contained excessive harmful tobacco components and required Philip Morris International to provide a risk assessment report and proof of potential harm. It remains to be seen whether the FDA will recognize the research report provided by Philip Morris International and whether it will allow IQOS products to enter the U.S. market, which could affect the status of some U.S. e-cigarette brands such as JUUL, V2, and Blu.
According to information released today by Philip Morris International, the clinical trial of its most advanced smoke-free tobacco product, IQOS, has concluded with positive results.
IQOSThe research report on IQOS published on the company's official website shows that the company studied the exposure response to the smoke of its smoke-free tobacco products. The study continuously tracked and measured the biological responses of consumers who switched to and used IQOS devices over a period of six months, comparing the final results with those of a group of continuous smokers. The results indicated that after six months, the group that switched to IQOS products showed improvements in eight biological response indicators (mainly clinical risk indicators). This is the latest research finding regarding the company's new product.
Frederic, the president of Philip Morris International's EU region
Earlier, Philip Morris International attempted to enter the U.S. market with IQOS but was rejected by the U.S. Food and Drug Administration (FDA), which claimed that the product contained excessive harmful tobacco components and required Philip Morris International to provide a risk assessment report and proof of potential harm. It remains to be seen whether the FDA will recognize the research report provided by Philip Morris International and whether it will allow IQOS products to enter the U.S. market, which could affect the status of some U.S. e-cigarette brands such as JUUL, V2, and Blu.
